Product image of Letrozol Aurovitas (Letrozole) supplied by GNH India

Letrozol Aurovitas

Active Ingredient:
Letrozole
Origin:
EU

Letrozol Aurovitas (Letrozole)

Letrozole, the active ingredient in Letrozol Aurovitas, is an aromatase inhibitor presented as an oral formulation for systemic use. It reduces estrogen production and is employed in the treatment of postmenopausal estrogen receptor‑positive breast cancer. By selectively blocking the aromatase enzyme, it limits peripheral conversion of androgens to estrogens, thereby slowing tumor growth in hormone‑sensitive disease.

GNH India supplies Letrozol Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Eugia Pharma (Malta) Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozol Aurovitas is an aromatase inhibitor used in hormone‑dependent breast cancer management.

  • Adjuvant treatment of postmenopausal ER‑positive breast cancer: reduces risk of recurrence after surgery.
  • Metastatic breast cancer in postmenopausal women: slows disease progression and improves survival.
  • Hormone‑responsive breast cancer in combination with other systemic therapies: enhances overall therapeutic effect.

How It Works

  • Letrozole acts as a reversible, non‑steroidal inhibitor of the aromatase enzyme, which catalyzes the conversion of adrenal and ovarian androgens to estrogens. By binding to the enzyme's active site, it markedly lowers circulating estrogen levels, depriving estrogen‑dependent tumor cells of growth stimulation and thereby inhibiting tumor proliferation.

Side Effects

Adverse reactions may occur with Letrozol Aurovitas and should be monitored.

Common Side Effects

  • Hot flashes: transient episodes of increased warmth.
  • Arthralgia: joint pain or stiffness.
  • Fatigue: persistent tiredness.
  • Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects

  • Severe liver injury: jaundice, elevated enzymes.
  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Bone fracture: increased risk due to lowered estrogen.
  • Severe allergic reaction: rash, swelling, difficulty breathing.

Precautions & Warnings

When prescribing Letrozol Aurovitas, consider the following precautions.

  • Assess bone health: monitor for osteoporosis and consider calcium/vitamin D supplementation.
  • Monitor liver function: periodic liver enzyme tests are recommended.
  • Evaluate cardiovascular risk: watch for signs of thromboembolic disease.
  • Avoid use in premenopausal women: drug is not indicated for this population.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Letrozol Aurovitas may interact with several medications; awareness of interaction severity is essential.

Major Interactions (Avoid)

  • Concurrent estrogen replacement therapy: antagonizes letrozole's effect.
  • Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce efficacy.
  • Tamoxifen: combined use can diminish anti‑estrogen activity.

Moderate Interactions (Monitor Closely)

  • Antifungal azoles (e.g., ketoconazole): may increase plasma concentrations.
  • Selective serotonin reuptake inhibitors (e.g., paroxetine): may modestly raise letrozole levels.
  • Warfarin: potential increase in INR, requiring closer coagulation monitoring.

Frequently Asked Questions

Letrozol Aurovitas contains letrozole, an aromatase inhibitor indicated for the treatment of postmenopausal estrogen receptor‑positive breast cancer. It is used in both adjuvant settings after surgery and in metastatic disease to reduce tumor growth driven by estrogen.

Letrozole reversibly binds to the aromatase enzyme, blocking the conversion of androgens to estrogens. This results in markedly lower circulating estrogen levels, depriving estrogen‑dependent breast cancer cells of a key growth stimulus and thereby inhibiting tumor proliferation.

The specific dose of Letrozol Aurovitas is determined by the prescribing physician based on the patient’s clinical condition, treatment setting, and individual factors. Healthcare professionals should follow local prescribing guidelines and adjust the regimen as needed.

Letrozole is contraindicated in pregnancy and is not recommended for use while breastfeeding. It may cause fetal harm, and women of child‑bearing potential should use effective contraception during treatment and for a period after discontinuation.

To order Letrozol Aurovitas, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozol Aurovitas (letrozole) is a third‑generation aromatase inhibitor with a high potency and a longer half‑life compared with anastrozole. Both drugs lower estrogen levels, but letrozole may achieve slightly greater estrogen suppression, which can translate into marginally improved disease control in some patients.

Letrozol Aurovitas should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct light to maintain stability throughout its shelf life.

Letrozol Aurovitas is taken orally, usually with a glass of water. It is generally administered once daily, and patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include severe liver injury, thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, bone fractures due to decreased estrogen, and rare but severe allergic reactions. Patients should be monitored regularly for signs of these conditions.

Letrozol Aurovitas should not be used in premenopausal women, individuals with known hypersensitivity to letrozole or any excipients, and patients with severe liver impairment. Contraindications also include pregnancy and breastfeeding.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT